PDS Biotechnology Corporation reports developments in targeted cancer immunotherapies based on its Versamune platform. Company news centers on PDS0101, also called Versamune HPV, in HPV16-positive head and neck cancer, and on PDS01ADC, an IL-12 fused antibody drug conjugate and tumor-targeted immunocytokine evaluated across multiple solid tumor indications.
Recurring updates include clinical-trial data, National Cancer Institute-led study presentations, FDA and IND protocol communications, scientific publications, patent coverage for core technology, quarterly financial results, and broader corporate-program updates.
PDS Biotechnology Corporation (Nasdaq: PDSB) has announced the dosing of the first patient in a Phase 2 clinical trial for PDS0101, targeting advanced HPV-associated cancers. Conducted by the National Cancer Institute (NCI), the study evaluates a combination of PDS0101 with Bintrafusp alfa and NHS-IL12 in approximately 35 patients. Initial safety and objective responses will be assessed from the first eight patients. This trial aims to enhance the efficacy of PDS0101 through the Versamune® platform, demonstrating its potential in improving outcomes for patients with advanced cancers.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced the publication of an abstract on preclinical studies of PDS0102 at the ASCO Virtual Scientific Program, indicating the Versamune® platform's efficacy in inducing strong killer T-cell responses across various tumors. The study shows that PDS0102, targeting prostate and breast cancers, can activate T-cells that specifically attack cancer cells expressing the TARP protein, associated with an anticipated 450,000 diagnoses this year. These findings demonstrate the potential versatility and effectiveness of the Versamune® technology in immuno-oncology.
PDS Biotechnology Corporation (PDSB) reported its financial results for Q1 2020, showing a net loss of approximately $4.0 million, or $0.39 per share, compared to a net income of $6.8 million in Q1 2019. Research and development expenses increased by 91% to $1.9 million while general and administrative expenses decreased by 47% to $2.1 million. The company initiated vaccine development for COVID-19 and influenza, and secured a U.S. patent for its Versamune® platform. As of March 31, 2020, PDSB held approximately $21.0 million in cash, including net proceeds from a public offering in February.
Summary not available.